Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for nemolizumab

  1. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)

    Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.

    Technology appraisal guidance
    Published
    2 July 2025
    View recommendations

    Sections for TA1077

  2. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ruxolitinib cream for treating moderate atopic dermatitis after topical corticosteroids and calcineurin inhibitors ID6602

    In development Reference number: GID-TA11809 Expected publication date:  03 June 2027

    Technology appraisal guidance
    In development